C-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis

Blood

Volumn 123, Issue 23, 2014, Pages 3585-3595

  Nanbakhsh, Arash ^a   Pochon, Cécile ^a   Mallavialle, Aude ^b   Amsellem, Sophie ^a   Bourhis, Jean Henri ^a   Chouaib, Salem ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYTARABINE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN KINASE B; UL 16 BINDING PROTEIN 1; UL 16 BINDING PROTEIN 2; UL 16 BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CYTOLYSIS; CYTOTOXICITY; GENETIC REGULATION; HL 60 CELL LINE; HUMAN; HUMAN CELL; KG 1 CELL LINE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL DEATH; CELLS, CULTURED; CYTARABINE; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GPI-LINKED PROTEINS; HL-60 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LIGANDS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84902189225     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-536219     Document Type: Article

References (53)

1. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37(6):649-658.
2. Rustum YM, Preisler HD. Correlation between leukemic cell retention of 1-beta-Darabinofuranosylcytosine 59-triphosphate and response to therapy. Cancer Res. 1979;39(1): 42-49. (Pubitemid 9090410)
3. Estey E. Treatment of refractory AML. Leukemia. 1996;10(6):932-936. (Pubitemid 26235922)
4. Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-Aza-29-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia. 1997; 11(suppl 1):S24-S27.
5. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ. Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA. 1982;248(19): 2481-2486. (Pubitemid 13233970)
6. Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121(1):26-28.
7. Wang WS, Tzeng CH, Chiou TJ, et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol. 1997;27(3):154-157.
8. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 2012;15(1-2):62-69.
9. Schiller GJ. Treatment of resistant disease. Leukemia. 1998;12(suppl 1):S20-S24. (Pubitemid 28478999)
10. Komada Y, Zhou YW, Zhang XL, et al. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Br J Haematol. 1997;96(1):147-157.
11. Debatin KM. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Inst. 1997; 89(11):750-751.
12. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst. 1997;89(11): 783-789. (Pubitemid 27242279)
13. Renvoizé C, Roger R, Moulian N, Bertoglio J, Bréard J. Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J Immunol. 1997; 159(1):126-134. (Pubitemid 127493693)
14. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997;11(11): 1833-1841. (Pubitemid 27485127)
15. Posovszky C, Friesen C, Herr I, Debatin KM. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95-and cytotoxic T-lymphocyte-mediatedapoptosis. Leukemia. 1999;13(3):400-409. (Pubitemid 29108079)
16. Classen CF, Fulda S, Friesen C, Debatin KM. Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity. Leukemia. 1999;13(3): 410-418. (Pubitemid 29108080)
17. Classen CF, Falk CS, Friesen C, Fulda S, Herr I, Debatin KM. Natural killer resistance of a drugresistant leukemia cell line, mediated by upregulation of HLA class I expression. Haematologica. 2003;88(5):509-521. (Pubitemid 36648440)
18. Treichel RS, Bunuan M, Hahn N, Wee K. Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell lineaffects susceptibility to killing by activated natural killer (NK) cells. Int J Cancer. 2004;108(1):78-85. (Pubitemid 37444447)
19. Bornhäuser M, Thiede C, Platzbecker U, et al.Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation inpatients with chronic myeloid leukemia. Blood. 2011;117(26):7174-7184.
20. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955-959.
21. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8): 3051-3057.
22. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503-510. (Pubitemid 351560519)
23. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006; 6(10):715-727. (Pubitemid 44453458)
24. Iannello A, Debbeche O, Samarani S, Ahmad A. Antiviral NK cell responses in HIV infection: I. NKcell receptor genes as determinants of HIVresistance and progression to AIDS. J Leukoc Biol. 2008;84(1):1-26. (Pubitemid 351960277)
25. Arina A, Murillo O, Dubrot J, et al. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther. 2007;7(5):599-615. (Pubitemid 46707184)
26. Manilay JO, Sykes M. Natural killer cells and their role in graft rejection. Curr Opin Immunol. 1998; 10(5):532-538. (Pubitemid 28479184)
27. Kroemer A, Edtinger K, Li XC. The innate natural killer cells in transplant rejection and tolerance induction. Curr Opin Organ Transplant. 2008; 13(4):339-343.
28. Ljunggren HG, Malmberg KJ. Prospects for theuse of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7(5):329-339.
29. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol. 2006;6(7):520-531. (Pubitemid 43980524)
30. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20(3): 123-137. (Pubitemid 43786166)
31. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428): 727-729.
32. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA. 1996;93(22): 12445-12450. (Pubitemid 26367163)
33. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD81 T cells. Blood. 2004;103(8):3065-3072. (Pubitemid 38451682)
34. Textor S, Dürst M, Jansen L, et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer. 2008;123(10):2343-2353.
35. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62(21): 6178-6186. (Pubitemid 35244469)
36. Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol. 2001;31(4): 1076-1086.
37. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10): 781-790. (Pubitemid 37328656)
38. Ogbomo H, Michaelis M, Klassert D, Doerr HW, Cinatl J Jr. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia. 2008;10(12):1402-1410.
39. Soriani A, Zingoni A, Cerboni C, et al. ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113(15):3503-3511.
40. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT. Proteasome regulation of ULBP1 transcription. J Immunol. 2009;182(10): 6600-6609.
41. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood. 2007;110(2):606-615. (Pubitemid 47105399)
42. López-Soto A, Quinõnes-Lombranã A, López-Arbesú R, López-Larrea C, González S. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem. 2006; 281(41):30419-30430. (Pubitemid 44582098)
43. Wu X, Tao Y, Hou J, Meng X, Shi J. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia. 2012;14(12):1178-1189.
44. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011;71(18):5998-6009.
45. Himmelreich H, Mathys A, Wodnar-Filipowicz A, Kalberer CP. Post-transcriptional regulation of ULBP1 ligand for the activating immunoreceptor NKG2D involves 39 untranslated region. Hum Immunol. 2011;72(6):470-478.
46. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186-1190. (Pubitemid 41232299)
47. Bortul R, Tazzari PL, Billi AM, et al. Deguelin, a PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol. 2005;129(5):677-686. (Pubitemid 40825830)
48. Bedel R, Thiery-Vuillemin A, Grandclement C, et al. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res. 2011;71(5): 1615-1626.
49. Noman MZ, Buart S, Van Pelt J, et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol. 2009;182(6): 3510-3521.
50. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005;19(4): 586-594. (Pubitemid 40521164)
51. Yin B, Morgan K, Hasz DE, Mao Z, Largaespada DA. Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia. 2006;20(1):151-154.
52. Unni AM, Bondar T, Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci USA. 2008;105(5):1686-1691. (Pubitemid 351346575)
53. She M, Niu X, Chen X, et al. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett. 2012;318(2):173-179.